Lilly Breaks Ground on $5B Antibody-Drug Conjugate Plant in Goochland, Virginia
Eli Lilly held a ceremonial groundbreaking on October 22 for its $5 billion manufacturing site in Goochland County, Virginia, built to make antibody-drug conjugates for cancer treatment. It is Lilly's first site to combine API production and finished medicines in one place. The first building is due to open in 2030 and the second in 2031.
Our summary of an article from Virginia Business. Read the original at Virginia Business
What It Means
Putting ADC payload chemistry, conjugation and finished product on one campus is a hard integration problem. Highly potent compound containment, segregated utilities and sterile operations all have to be designed, qualified and validated together. With buildings opening in 2030 and 2031, this site will need years of steady engineering and CQV work, and its phasing is worth watching for anyone planning a multi-modality facility.
Read the original at Virginia Business.
